Trimethylamine oxide (Trimetlylamine oxide, TMAO) is a small molecule organic compound. In 2011, Cleveland Laboratory, one of the world's top cardiovascular disease medical centers, reported in Nature that TMAO, a metabolite of intestinal bacteria, is related to heart disease. , bringing the small molecule TMAO into the public view.
Targeted metabolomics can collect metabolome data of biological samples through MRM mode for target metabolites of interest to achieve qualitative analysis of metabolites. Combining the external standard quantitative method allows for the absolute quantification of metabolites in the sample using the standard curve of the standard.
TMAO is a low-molecular-weight amine compound with a relatively high content in aquatic products. It is also a metabolite related to intestinal flora. In the human body, intestinal bacteria can metabolize choline and lecithin to produce trimethylamine (TMA), which is then metabolized into TMAO. Trimethylamine oxide also exists in mammals, plants and fungi. Trimethylamine oxide and its metabolites participate in many important biological functions of the body, such as regulating osmotic pressure, stabilizing proteins, preventing protein denaturation, and participating in cell division. Studies have shown that elevated levels of TMAO are significantly positively correlated with cardiovascular diseases, and are closely related to hypertension, cardiac insufficiency, arteriosclerosis and other diseases. Therefore, trimethylamine oxide has received more and more attention. The study of trimethylamine oxide and related metabolites has important reference value in exploring TMAO metabolism, pathogenesis of related diseases, diagnosis, treatment and prevention methods.
Our TMAO Analysis Service
With integrated set of separation, characterization, identification and quantification systems featured with excellent robustness & reproducibility, high and ultra-sensitivity, Creative Proteomics provides reliable, rapid and cost-effective TMO targeted metabolomics services.
Creative Proteomics has established a robust, reproducible, and highly sensitive HPLC-MS platform for the simultaneous quantification of TMAO. Our high-throughput TMAO detection and analysis technology is based on LC-MS/MS and allows for the absolute quantitative detection of TMAO and its metabolites, including Trimethylamine N-oxide, Trimethylamine, Choline (Choline), Betaine, Creatinine, and L-carnitine. Complete quantitative analysis of TMAO and related metabolites can provide a reliable basis for the study of the etiology and pathology of related diseases.
Advanced Platform: We utilize AB SCIEX QTRAP 6500+, a high-precision and high-resolution targeted detection mass spectrometer, to achieve precise and accurate targeted identification.
Self-built Database: We have independently built the TMAO metabolite database and provided all standard curves for measured substances.
Strict Quality Control: Our dual quality control system includes Standard QC, Sample QC, and exogenous internal standards to ensure data stability and accuracy.
Accurate Qualitative Results: Each compound has more than two pairs of characteristic ion pairs to ensure qualitative accuracy.
Accurate Quantitative Results: We use MRM mode with a triple quadrupole to accurately detect the relative content of substances.
Wide Linear Range: Our correlation coefficient is greater than 0.99, enabling us to perform quantitative analysis on different types of complex samples.
Gut flora research
Cardiovascular research, renal disease research, etc.
Identification of neurotransmitters in samples such as tissue cells;
Research on the pathogenesis of nervous system diseases;
|Analysis Type||Analysis Content|
|Difference Analysis||Univariate Statistical Analysis T Test|
|Functional Analysis||Hierarchical Cluster Analysis|
|Advanced Bioinformatics Analysis||Regression Analysis|
|Trend Cluster Analysis|
|Machine Learning ROC|
|Metabolites Quantified in This Service|
|Trimethylamine N-oxide (TMAO)|
Blood (serum, plasma) ≥200 μL
Animal tissue ≥120 mg
Feces ≥200 mg
- Long-Term Changes in Gut Microbial Metabolite Trimethylamine N-Oxide and Coronary Heart Disease Risk. Journal of the American College of Cardiology. 2020.
- Development of a gut microbe–targeted nonlethal therapeutic to inhibit thrombosis potential. Nature Medicine, 2018.